This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Insiders Love Right Now

Synageva BioPharma

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One biopharmaceutical player that insiders are loading up on here is Synageva BioPharma ( GEVA), which is focused on the discovery, development and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Insiders are buying this stock into solid strength, since shares are up 43% so far in 2013.

Synageva BioPharma has a market cap of $1.97 billion. Its estimated growth rate for this year is -73.2%, and for next year it's pegged at -22.8%.

>>4 Biotech Stocks Under $10 Making Big Moves

A director just bought 1.05 million shares, or about $59.46 million worth of stock, at $56.63 per share.

From a technical perspective, GEVA is currently trending well above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $44.52 to its intraday high of $68.25 a share. During that uptrend, shares of GEVA have been consistently making higher lows and higher highs, which is bullish technical price action. That said, shares of GEVA have now entered extremely overbought territory, since its current relative strength index reading is 89.

If you're bullish on GEVA, then look for long-biased trades after this stock has cooled off and worked off some of its overbought conditions. I would look for a pullback back toward $62.50 or $60 a share to potentially get long shares of GEVA. Keep in mind that as long as GEVA is trending above its key breakout level of $55, then it remains in a very bullish uptrend.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
GEVA $238.60 1.19%
WFT $11.07 5.53%
CPRT $39.13 5.19%
CHEF $19.28 0.94%
NSH $24.03 2.12%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs